Update on sunscreens distributed by major US retailers that meet American Academy of Dermatology recommendations To the Editor: In 2014, Yazdani et al published an article detailing the proportion of sunscreens distributed by the largest United States retailer (Walmart, Bentonville, AR) and pharmacy (Walgreens, Deerfield, IL) that met American Academy of Dermatology (AAD) recommendations: 1) sun protection factor (SPF) $30, 2) broad-spectrum coverage, and 3) water resistant for 40-80 minutes. 1, 2 These recommendations were released following standardization of sunscreen labeling and effectiveness testing by the Food and Drug Administration in 2011. 3, 4 The authors also determined whether products that included tanning or bronzing on their primary display panel were less likely to meet these recommendations. In their study, Yazdani and colleagues found that only 34.5% of sunscreens sold at the largest US retailer and 41.0% of sunscreens sold at the largest US pharmacy retailer met all AAD recommendations. In addition, tanning and bronzing products were significantly less likely to meet AAD recommendations.
We conducted a follow-up to this study in January 2017 to determine if a greater percentage of sunscreens and tanning and bronzing products now meet AAD guidelines. Table I ). Our findings demonstrate that significantly more products with broad-spectrum coverage and water resistance are available to consumers in 2017 than in 2014 (P\.01). The proportion of products with SPF $30 remained stable, possibly because there were already many to begin with. In addition, significantly more sunscreens met all 3 AAD recommendations in 2017 compared with the sunscreens available in 2014 (P \.01). Furthermore, in accordance with the previous study, tanning and bronzing products were significantly less likely to comply with all 3 AAD guidelines recommendations than other sunscreens (19.0% and 20.0%) (P \ .01) (Table II) . This lack of adherence might be due to the targeted consumer population. Consumers may equate a higher SPF to receiving less of a tan.
Our study demonstrates that sunscreens available at major retailers more closely adhere to AAD To the Editor: Pemphigus is characterized by acquired autoantibodies to desmosomal cadherins. The only US Food and Drug Administrationeapproved treatment is corticosteroids (often given chronically at high doses). 1 Although mortality rates have declined with their use, corticosteroids are associated with serious dose-dependent complications. 2 To help physicians assess the risks of oral corticosteroid (OCS) treatment in this special patient population, we sought to quantify glucocorticoid-related adverse event (GAE) risk according to cumulative OCS exposure among patients with newly diagnosed pemphigus and to estimate the associated cost.
We conducted a retrospective cohort study with the use of Truven Health MarketScan administrative claims data. The study included patients $18 years of age with newly diagnosed (no diagnosis in 6 months before first observed) pemphigus, defined as $2 claims from July 1, 2010, to December 31, 2013, with ICD-9-CM code of 694.4 3 and OCS use 6 months before (baseline), to include empiric treatment, or after first diagnosis. Enrollment occurred during baseline and $1 year after first pemphigus diagnosis. On the basis of expert input and literature review, 4 11 GAE categories were selected: cardiovascular events, opportunistic infection, cataract, osteoporosis, fracture, ulcer, aseptic necrosis, glaucoma, type 2 diabetes, psychosis, and hypertension. Chronic GAEs were counted if absent during baseline. We used Cox proportional hazards to estimate GAE risk with cumulative prednisone-equivalent grams exposure (updated daily from start of baseline) as the predictor variable. We adjusted for age, sex, and number of chronic conditions. Mean first-year costs were compared between patients with GAE and those without GAE through the use of t tests.
For the 644 patients included, mean age was 59.5 years and 56.1% were female (Table I) . Mean total and daily OCS dose in the first year of follow-up was 3.9 g (median, 2.2 g) and 29.0 mg (median, 20.0 mg), respectively. The overall GAE rate was 0.46 events per patient-year. GAE risk increased per 1 g OCS exposure (hazard ratio [HR], 1.01; P ¼ .03), as did the risk of cataract (HR, 1.02; P \ .001) and fracture (HR, 1.01; P ¼ .03) ( Table II) . The risks of infection, osteoporosis, necrosis of bone, psychosis, glaucoma, and diabetes were not statistically significantly associated with OCS. In the first follow-up year, patients with GAE compared with those without GAE had greater overall healthcare costs ($46,250 vs $24,962; P \ .001), medical costs ($41,534 vs $21,528; P ¼ .002), and outpatient pharmacy costs ($4716 vs $3433; P ¼ .018).
Our results show that pemphigus patients with high OCS exposure have a greater risk of cataract and fracture. Each gram of OCS increases the risk of any GAE by 1%, risk of cataract by 2%, and risk of fracture by 1%. Previous studies in rheumatoid arthritis, asthma, and systemic lupus found similarly increased risks of fracture and cataracts as well as diabetes and infection. 
